Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IDYA logo IDYA
Upturn stock ratingUpturn stock rating
IDYA logo

Ideaya Biosciences Inc (IDYA)

Upturn stock ratingUpturn stock rating
$24.61
Last Close (24-hour delay)
Profit since last BUY20.22%
upturn advisory
Regular Buy
BUY since 93 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/12/2025: IDYA (3-star) is a REGULAR-BUY. BUY since 93 days. Simulated Profits (20.22%). Updated daily EoD!

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

13 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $46.88

1 Year Target Price $46.88

Analysts Price Target For last 52 week
$46.88 Target price
52w Low $13.45
Current$24.61
52w High $37.8

Analysis of Past Performance

Type Stock
Historic Profit 83.02%
Avg. Invested days 55
Today’s Advisory Regular Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/12/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.16B USD
Price to earnings Ratio -
1Y Target Price 46.88
Price to earnings Ratio -
1Y Target Price 46.88
Volume (30-day avg) 13
Beta 0.12
52 Weeks Range 13.45 - 37.80
Updated Date 09/14/2025
52 Weeks Range 13.45 - 37.80
Updated Date 09/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.84

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -5488.94%

Management Effectiveness

Return on Assets (TTM) -23.84%
Return on Equity (TTM) -35.09%

Valuation

Trailing PE -
Forward PE 4.65
Enterprise Value 1513770112
Price to Sales(TTM) 308.13
Enterprise Value 1513770112
Price to Sales(TTM) 308.13
Enterprise Value to Revenue 216.25
Enterprise Value to EBITDA -7.8
Shares Outstanding 87643696
Shares Floating 81816257
Shares Outstanding 87643696
Shares Floating 81816257
Percent Insiders 0.91
Percent Institutions 115.11

ai summary icon Upturn AI SWOT

Ideaya Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Ideaya Biosciences Inc. was founded in 2010. The company focuses on discovering and developing targeted oncology therapeutics. It has evolved from a research-focused organization to a clinical-stage biopharmaceutical company.

business area logo Core Business Areas

  • Small Molecule Discovery and Development: Focuses on identifying and developing small molecule inhibitors that target critical pathways in cancer cells.
  • Synthetic Lethality: Utilizes synthetic lethality approaches to target tumors with specific genetic mutations or dependencies.
  • Preclinical and Clinical Research: Conducts preclinical studies and clinical trials to evaluate the safety and efficacy of its drug candidates.

leadership logo Leadership and Structure

Darren Eckert is the current CEO. The company has a board of directors and various functional departments including research, development, clinical operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • IDE196 (Darovasertib): A protein kinase C (PKC) inhibitor being developed for genetically defined cancers, including metastatic uveal melanoma (MUM). Market share data is not publicly available. Competitors in this area include companies developing targeted therapies for MUM. Revenue from this product is not yet available.
  • IDE397 (MAT2A inhibitor): A small molecule inhibitor of methionine adenosyltransferase 2A (MAT2A) being developed for tumors with methylthioadenosine phosphorylase (MTAP) deletions. Market share data is not publicly available. Competitors include other companies pursuing MAT2A or related targets. Revenue from this product is not yet available.
  • Vactosertib (TGF-beta inhibitor): Ideaya Biosciences is studying this in combination with other treatments. Market share data is unavailable. Main competitors are other TGF-beta inhibitors in the market, such as Debio 0123. Revenue is currently not available.

Market Dynamics

industry overview logo Industry Overview

The oncology therapeutics market is characterized by intense competition, rapid innovation, and high regulatory hurdles. It's driven by the growing incidence of cancer and advancements in personalized medicine.

Positioning

Ideaya Biosciences is positioned as a company focused on precision medicine and synthetic lethality approaches, targeting specific genetic vulnerabilities in cancer. Its competitive advantage lies in its expertise in these areas and its pipeline of novel drug candidates.

Total Addressable Market (TAM)

The oncology therapeutics market is estimated to be worth hundreds of billions of dollars. Ideaya Biosciences is positioned to capture a portion of this TAM by developing targeted therapies for specific cancer subtypes.

Upturn SWOT Analysis

Strengths

  • Strong expertise in synthetic lethality and precision medicine
  • Proprietary drug discovery platform
  • Pipeline of novel drug candidates targeting specific genetic vulnerabilities in cancer
  • Strategic collaborations with leading pharmaceutical companies

Weaknesses

  • Clinical trial risk and regulatory hurdles
  • Limited financial resources compared to larger pharmaceutical companies
  • Dependence on key partnerships
  • No approved products generating revenue

Opportunities

  • Expansion of pipeline through internal discovery and external collaborations
  • Potential for breakthrough therapies in genetically defined cancers
  • Partnerships with larger pharmaceutical companies for late-stage development and commercialization
  • Acquisition by a larger pharmaceutical company

Threats

  • Competition from larger pharmaceutical companies with more resources
  • Failure of clinical trials
  • Regulatory setbacks
  • Patent challenges
  • Economic downturn affecting funding for biotechnology companies

Competitors and Market Share

competitor logo Key Competitors

  • Mirati Therapeutics Inc (MRTX)
  • Repare Therapeutics Inc (RPTX)
  • Kura Oncology Inc (KURA)

Competitive Landscape

Ideaya faces competition from other biotechnology and pharmaceutical companies developing targeted oncology therapeutics. Its competitive advantage lies in its focus on synthetic lethality and precision medicine approaches. All the competitors in the Market Share Comparison are at the same clinical stage

Growth Trajectory and Initiatives

Historical Growth: Ideaya Biosciences' historical growth has been characterized by the expansion of its pipeline and the establishment of strategic collaborations.

Future Projections: Future growth is dependent on the success of its clinical trials, regulatory approvals, and the expansion of its pipeline. Analyst estimates vary but generally project revenue growth based on potential product launches and continued collaboration revenue.

Recent Initiatives: Recent strategic initiatives include advancing its lead drug candidates through clinical trials, expanding its collaborations with pharmaceutical companies, and exploring new therapeutic targets.

Summary

Ideaya Biosciences is a clinical-stage biopharmaceutical company with a focus on precision medicine for oncology. Its strengths lie in its expertise in synthetic lethality and its pipeline of novel drug candidates. The company faces challenges typical of clinical-stage biotechs, including clinical trial risk and limited financial resources. Ideaya needs to manage its cash runway and partnership dependencies to achieve its goals.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Press Releases

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated and may not be precise. Financial performance is as of the last available data and is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Ideaya Biosciences Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2019-05-23
Founder, President, CEO & Director Mr. Yujiro S. Hata
Sector Healthcare
Industry Biotechnology
Full time employees 131
Full time employees 131

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.